Choose a language and wait for the translated text.
Shots:
Merck & Moderna have reported detailed data from the P-III (INTerpath-001) trial evaluating intismeran autogene + Keytruda vs Keytruda alone as adjuvant treatment in 1,137 pts with completely resected stage IIB-IV melanoma; data will be presented at ESMO 2026 & accepted for publication in NEJM
At a median follow-up of 24.6mos, the combination reduced the risk of recurrence or death by 42% (HR=0.58; p<0.001) & the risk of distant metastasis or death by 38% (HR=0.62; p=0.002), with 2yr RFS rates of 82.2% vs 70.0%
OS data are not yet mature, with a favorable trend observed; no new safety signals were seen & the companies are engaging with regulatory authorities
Ref: Business Wire | Image: MSD & Moderna | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Merck and Moderna Report P-III (INTerpath-001) Trial Data of Intismeran Autogene + Keytruda for Resected Melanoma at ESMO 2026 appeared first on PharmaShots.
